DNA testing to explain who gets severe blood pressure with bevacizumab
Part of Cancer, Skin clinical trials.
This study uses whole exome DNA testing to look for inherited genetic differences that may explain why some people develop very high blood pressure from bevacizumab during breast cancer treatment. It compares people who did vs. did not develop severe bevacizumab-related hypertension.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a European American patient with available DNA for testing
- You must have been treated with bevacizumab for breast cancer
- You developed severe (grade 3–4) hypertension caused by bevacizumab during treatment
- You were able to provide DNA samples and your sample can be used as a case or control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses DNA genetic testing to find DNA changes that might explain why some people develop heart failure (CHF) after breast cancer treatment with certain medicines. It may help researchers understand risk and improve care for future patients.
This study uses genetic tests on blood DNA to look for differences that may explain why some people develop nerve pain (peripheral neuropathy) from paclitaxel used for breast cancer. It compares people who got significant neuropathy during treatment with people who did not get neuropathy after completing paclitaxel.
This study is testing a new blood test (liquid biopsy) to see if it can accurately detect breast cancer or track remission. If you are a woman getting a mammogram, have an abnormal finding, were recently diagnosed, or are in remission after treatment, you may be able to join and help validate this test.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
This study looks for DNA fragments in blood of people with certain inherited cancer syndromes. It may help find cancer earlier or guide better monitoring. You would give blood samples every 4 months (if in the experimental group).
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
Hear when a new Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.